{"organizations": [], "uuid": "36e1217fc145ffcd80b5455dddf5edfad43c3cae", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/abbvie-fda/fda-extends-review-for-abbvie-neurocrines-uterine-pain-drug-idUSL3N1RN4LV", "country": "US", "domain_rank": 408, "title": "FDA extends review for AbbVie, Neurocrine's uterine pain drug", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T15:24:00.000+03:00", "replies_count": 0, "uuid": "36e1217fc145ffcd80b5455dddf5edfad43c3cae"}, "author": "", "url": "https://www.reuters.com/article/abbvie-fda/fda-extends-review-for-abbvie-neurocrines-uterine-pain-drug-idUSL3N1RN4LV", "ord_in_thread": 0, "title": "FDA extends review for AbbVie, Neurocrine's uterine pain drug", "locations": [], "entities": {"persons": [{"name": "bernard orr", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}, {"name": "abbvie", "sentiment": "none"}, {"name": "elagolix", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "neurocrine", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "neurocrine biosciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10, 2018 / 12:27 PM / Updated 15 minutes ago FDA extends review for AbbVie, Neurocrine's uterine pain drug Reuters Staff 1 Min Read \nApril 10 (Reuters) - AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. \nThe agency requested additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said. \nThe FDA is now expected to make its decision in the third quarter of 2018, three months later than initially expected. (Reporting by Tamara Mathias in Bengaluru; Editing by Bernard Orr)", "external_links": [], "published": "2018-04-10T15:24:00.000+03:00", "crawled": "2018-04-10T15:48:49.021+03:00", "highlightTitle": ""}